Selecta Biosciences Inc (NASDAQ:SELB) hit a new 52-week low during trading on Thursday . The stock traded as low as $10.53 and last traded at $10.59, with a volume of 21,958 shares. The stock had previously closed at $11.57.

Several research firms have issued reports on SELB. Stifel Nicolaus began coverage on Selecta Biosciences in a report on Monday, July 18th. They issued a “buy” rating and a $23.00 price target on the stock. Needham & Company LLC began coverage on Selecta Biosciences in a report on Monday, July 18th. They issued a “buy” rating and a $28.00 price target on the stock. Finally, Canaccord Genuity began coverage on Selecta Biosciences in a report on Monday, July 18th. They issued a “buy” rating and a $20.00 price target on the stock.

The stock’s 50-day moving average is $13.62 and its 200-day moving average is $13.62.

In other news, Director Amir Nashat acquired 150,000 shares of the firm’s stock in a transaction on Monday, June 27th. The shares were purchased at an average cost of $14.00 per share, with a total value of $2,100,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Nanodimension Management Ltd acquired 385,000 shares of the firm’s stock in a transaction on Monday, June 27th. The shares were purchased at an average cost of $14.00 per share, for a total transaction of $5,390,000.00. The disclosure for this purchase can be found here.

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.